Ex-Sun Employee Alleges Reprisal For Opposing US Off-Label Practices
Executive Summary
A Sun Pharma executive dismissed earlier this year has claimed retaliation by the company after she objected to the Indian firm’s alleged off-label marketing practices. Sun refutes the allegations and vows to vigorously defend itself, while experts suggest a settlement may be the way forward.
You may also be interested in...
Sun Fights US Charges Over Delays
Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.
Concerns Over Alleged Lapses By Sun Fading?
Early indications that a whistleblower’s allegations of certain serious irregularities by Sun Pharma may not hold water lifted its shares, though it remains unclear if the issue stands completely closed.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.